Development of National Antimicrobial Intravenous-to-Oral Switch Criteria and Decision Aid

Author:

Harvey Eleanor J.1,Hand Kieran2ORCID,Weston Dale3,Ashiru-Oredope Diane14ORCID

Affiliation:

1. Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London SW1P 3JR, UK

2. Antimicrobial Resistance Programme, NHS England, London SE1 8UG, UK

3. Behavioural Science and Insights Unit, UK Health Security Agency (UKHSA), Porton Down, Salisbury SP4 0JG, UK

4. School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK

Abstract

Introduction: Antimicrobial stewardship (AMS) strategies, such as intravenous-to-oral switch (IVOS), promote optimal antimicrobial use, contributing to safer and more effective patient care and tackling antimicrobial resistance (AMR). Aim: This study aimed to achieve nationwide multidisciplinary expert consensus on antimicrobial IVOS criteria for timely switch in hospitalised adult patients and to design an IVOS decision aid to operationalise agreed IVOS criteria in the hospital setting. Method: A four-step Delphi process was chosen to achieve expert consensus on IVOS criteria and decision aid; it included (Step One) Pilot/1st round questionnaire, (Step Two) Virtual meeting, (Step Three) 2nd round questionnaire and (Step 4) Workshop. This study follows the Appraisal of Guidelines for Research and Evaluation II instrument checklist. Results: The Step One questionnaire of 42 IVOS criteria had 24 respondents, 15 of whom participated in Step Two, in which 37 criteria were accepted for the next step. Step Three had 242 respondents (England n = 195, Northern Ireland n = 18, Scotland n = 18, Wales n = 11); 27 criteria were accepted. Step Four had 48 survey respondents and 33 workshop participants; consensus was achieved for 24 criteria and comments were received on a proposed IVOS decision aid. Research recommendations include the use of evidence-based standardised IVOS criteria. Discussion and Conclusion: This study achieved nationwide expert consensus on antimicrobial IVOS criteria for timely switch in the hospitalised adult population. For criteria operationalisation, an IVOS decision aid was developed. Further research is required to provide clinical validation of the consensus IVOS criteria and to expand this work into the paediatric and international settings.

Funder

UK Health Security Agency

Publisher

MDPI AG

Subject

General Medicine

Reference50 articles.

1. HM Government (2022, September 20). Tackling Antimicrobial Resistance 2019–2024: The UK’s Five-Year National Action Plan, Available online: https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2019-to-2024.

2. CDC (2022, September 20). Core Elements of Hospital Antibiotic Stewardship Programs, Available online: https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf.

3. Interventions to improve the review of antibiotic therapy in acute care hospitals: A systematic review and narrative synthesis;Matuluko;JAC Antimicrob. Resist.,2020

4. World Health Organization (2022, October 27). Library of AMR National Action Plans. Available online: https://www.who.int/teams/surveillance-prevention-control-AMR/national-action-plan-monitoring-evaluation/library-of-national-action-plans.

5. Government of Canada (2022, September 20). Federal Action Plan on Antimicrobial Resistance and Use in Canada: Building on the Federal Framework for Action, Available online: https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/federal-action-plan-antimicrobial-resistance-canada.html.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3